---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-038112"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2024-09-25T23:59:59+00:00"
generated_at: "2026-05-31T01:53:17.497691+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Anebulo Pharma reports Q4 FY2024 net loss $0.05/share; net loss down 48% YoY; awarded $1.9M NIDA grant

## Summary
- Q4 FY2024 net loss $1.3M ($0.05/sh) vs $2.5M ($0.10/sh) in Q4 FY2023.
- Full-year FY2024 net loss $8.2M ($0.32/sh) vs $11.7M ($0.47/sh) in FY2023.
- Cash and equivalents $3.1M at June 30, 2024; additional $10M available under loan agreement.
- Awarded up to $1.9M NIDA grant for IND-enabling activities for IV selonabant for pediatric cannabis poisoning.
- Expects to enroll first healthy volunteer in H1 2025 for IV formulation clinical study.

## SEC filing metadata
- accession: 0001493152-24-038112
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2024-09-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315224038112/0001493152-24-038112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315224038112/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-038112
- JSON: https://secwatch.observer/filing/0001493152-24-038112.json
- Plain text: https://secwatch.observer/filing/0001493152-24-038112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.